Healthcare Industry News: cryoablation
News Release - May 1, 2007
ATS 3f Aortic Bioprosthesis Experience Presented at ACTS 2007MINNEAPOLIS, May 1 (HSMN NewsFeed) -- ATS Medical, Inc. (Nasdaq: ATSI ) today announced that noted cardiologist, Dr. Xu Yu Jin from the Department of Surgery at the John Radcliffe Hospital in Oxford, U.K. will present their experience with the ATS 3f® Aortic Bioprosthesis during the upcoming Advanced Cardiac Techniques in Surgery conference sponsored by the Lenox Hill Heart and Vascular Institute of New York.
Dr. Jin's presentation scheduled for 10:30 AM on Wednesday, May 2 is entitled "Implantation Technique and Implication of 3f Stentless Valve Design for Aortic Root Geometry." It will open with a video of the implant procedure as performed by Mr. Ravi Pillai, MD, FRCS. Dr. Jin will follow with a review of the clinical follow up supporting his observations that the ATS 3f Aortic Bioprosthesis is the only valve replacement that fully preserves native aortic root geometry. Further, he will elaborate on how this may be crucial to enhanced long term durability and improved clinical performance.
Michael Dale, President and CEO of ATS noted, "By design, the ATS 3f Aortic Bioprosthesis is intended to provide a more natural and durable solution to the treatment of aortic valve disease by maintaining the continuity and integrity of the aortic root. Based on extensive clinical experience with the 3f valve, Dr. Jin and his colleagues have been able to provide surgeons and patients novel clinical evidence lending confirmation of the unique benefits of the patented 3f tubular valve design. Based on this clinical evidence and other pending reports we believe 3f represents a rewarding growth opportunity for ATS and a better clinical solution for patients."
The highly regarded ACTS 2007 gathering on May 2 and 3 will focus on the latest surgical and interventional therapies for heart valve and coronary artery diseases, chronic atrial fibrillation and diseases of the aorta. The meeting will be held at The Equitable Center & Sheraton New York Hotel and Towers. The agenda and meeting details are available at http://www.promedicacme.com/conf_acts2007.htm.
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The company, global in scope, is headquartered in Minneapolis, Minnesota. More than 135,000 ATS Open Pivot® Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3F® brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(TM) annuloplasty products for heart valve repair, SurgiFrost® and FrostByte(TM) products for surgical cryoablation of cardiac arrhythmias, RTI-Cardiovascular for allograft tissue services, and the development of PARSUS blood filtration technology. The ATS Medical web site is http://www.atsmedical.com.
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3F Therapeutics, regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2006.
Source: ATS Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.